The Exploration of OX40 (CD134) Expression Levels in Sarcoma Specimens and Its Clinical Application in Prognosis Determination

NCT06751251 · tracked via the Priya Life Science China tracker

Sponsor

Peking University People's Hospital

Phase

Observational

Started

2025-01-01

Last updated

2025-07-10

Condition(s) studied

SarcomaBiomarkersProgression

Investigational drug(s) / intervention(s)

IHC: ImmunohistochemistryRNA-seq

IHC: Immunohistochemistry: Immunohistochemistry will be implied in tissue sections to test the expression of OX4O in sarcoma.

RNA-seq: RNA-seq will be implied in tissue sections to test the expression of CD134 RNA expression in sarcoma.

Study summary

This study aims to investigate the expression of OX40 (CD134) in sarcomas and its impact on prognosis, with the goal of identifying novel biomarkers for early resistance detection and optimizing treatment strategies for sarcoma patients. Sarcomas are a highly heterogeneous group of malignant tumors, for which current treatment options are often suboptimal in certain patients, and effective biomarkers to guide therapy are lacking. As a T-cell costimulatory receptor, OX40 plays a significant role in immune regulation across various solid tumors and holds promise as a potential therapeutic target.

The researcher's team has previously identified high OX40 expression in sarcomas through database analysis and validated the therapeutic efficacy of antibody-drug conjugates targeting OX40 in in vivo experiments using sarcoma cell lines in murine models. This study will evaluate the mRNA expression levels of OX40 in tumor tissues from sarcoma patients and assess OX40 protein expression using immunohistochemical staining. By integrating these findings with clinical and pathological data, the study will explore the potential of OX40 expression levels in tumor tissues as biomarkers for predicting treatment response and prognosis in primary bone tumors. The results aim to provide scientific evidence for the clinical application of OX40-targeted therapies and to propose novel therapeutic strategies to improve survival outcomes in sarcoma patients.

Eligibility

Sex

ALL

Min age

8 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Aged 8 years or older. * Diagnosed with high-grade osteosarcoma or Ewing sarcoma, confirmed through clinical evaluation or histopathological examination. For patients with localized tumors or solitary pulmonary lesions, pathological confirmation is required; for patients with multiple pulmonary metastases, pathological examination is not necessary. * Treatment-naïve patients who have not received standard first-line chemotherapy regimens for osteosarcoma or Ewing sarcoma.(First-line chemotherapy drugs include high-dose methotrexate, anthracyclines, cisplatin, and ifosfamide. For Ewing sarcoma, the standard first-line regimen is VDC followed by IE.) * All other examination indicators suggest that the patient is eligible for standardized chemotherapy and surgical treatment for bone tumors. Exclusion Criteria: * Inability to undergo standardized chemotherapy and surgical treatment for bone tumors at this center. * Refusal to adhere to follow-up according to standardized diagnostic and treatment protocols. * Any condition that, in the investigator's opinion, may harm the participant or prevent them from meeting or complying with the study requirements.

Primary outcome measure(s)

correlation of quantity of Protein OX40 Expression with clinical evaluation — 6 months
Clinical evaluation according to RECIST 1.1

Trial sites (1)

Facility	City	Region	Status
Peking University People's Hospital	Beijing	Beijing Municipality

More Peking University People's Hospital trials in China

Primary Cervical Cancer Screening by Self-sampling HPV Test Active, not recruiting

Evaluation of an EpCAM-Targeted Radiotracer in Epithelial Tumors Recruiting

Haplo-HSCT for Myelofibrosis Recruiting

Mass Spectrometry-based Immune Profiling in Autoimmune Diseases Enrolling by invitation

PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer Recruiting

Other trials for the same condition

A Multiple-center Study on the Effect of Different Ways of Lymph Node Dissection on the Prognosis of Ground Glass Nodules Smaller Than 3cm and With More Than 50% Solid Components Recruiting

Preoperative Spatially Fractionated Radiation Therapy (SFRT) in Soft Tissue Sarcoma (neoSFRT-SARC) Recruiting

Combination Immunotherapy Targeting Sarcomas Starting soon

Application of Biomarkers in Neurological Diseases Recruiting

Surufatinib in Patients With Osteosarcoma and Soft Tissue Sarcoma Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06751251 on ClinicalTrials.gov ↗ ← All trials in China